%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2018-04-14T21:26:15+05:30
2018-04-14T21:26:16+05:30
2018-04-14T21:26:16+05:30
Adobe InDesign CS6 (Macintosh)
uuid:334b01e8-ef7a-2348-846d-9f4bbb922804
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.id:52B0164F152068118083B9AC9EB36DFC
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2018-04-14T21:26:16+05:30
xmp.iid:FF7F117407206811822AB50A4B5D35C6
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.did:01801174072068118DBB881A9EDFAAFA
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
6 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
25 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
11 0 0 11 579.4999 54.4294 Tm
(3)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
0 0 0 1 K
q 1 0 0 1 45 415.9917 cm
0 0 m
258 0 l
S
Q
q 1 0 0 1 45 226.4917 cm
0 0 m
258 0 l
S
Q
BT
/C2_0 1 Tf
0.015 Tc -0.015 Tw 11 0 0 11 45 697.9917 Tm
[<0044005100470003>-294.7<00500052005600570003>-294.7<00550048004F004C00440045004F00480003>-294.7<005000480057004B0052004700560003>-294.7<0049005200550003>-294.7<004A0048005100480057004C00460003>-294.7<005000520047004C00BF00460044>]TJ
/TT0 1 Tf
0 Tc 0 Tw (-)Tj
0.015 Tc 0.159 Tw 0 -1.182 TD
[(tion. )0.5(Currently)74.2(, )0.5(there )0.5(are )0.5(two )0.5(FDA-approved )0.5(viral-)]TJ
/Span<>> BDC
23.455 0 Td
( )Tj
EMC
0.308 Tw -23.455 -1.182 Td
[(mediated delivery products for use in the USA.)15.1( )]TJ
0.051 Tw 0 -1.182 TD
[(Luxturna \(voretigene neparvovec\) is an )55.4(AA)74.2(V)55.2(-based)14.8( )]TJ
/C2_0 1 Tf
-0.015 Tw 0 -1.182 TD
[<004700550058004A0003>-100.8<00450048004C0051004A0003>-100.8<00580056004800470003>-100.8<005700520003>-100.8<005700550048004400570003>-100.8<0045004C0044004F004F0048004F004C00460003>-100.8<003500330028001900180003>]TJ
/Span<>> BDC
19.166 0 Td
<0003>Tj
EMC
0 0 TD
<00500058005700440057004C005200510010>Tj
/TT0 1 Tf
0 Tc 0 Tw 4.288 0 Td
( )Tj
0.015 Tc 0.311 Tw -23.455 -1.182 Td
[(associated retinal dystrophy)74.2(. Imlygic \(talimogene)14.8( )]TJ
/C2_0 1 Tf
-0.015 Tw 0 -1.182 TD
[<004F0044004B0048005500530044005500480053005900480046000C0003>-132.4<004C00560003>-132.4<00440003>-132.5<005000520047004C00BF004800470003>-132.5<004B004800550053004800560003>-132.4<0056004C00500053004F0048005B0003>-132.4<0059004C005500580056>15<0003>]TJ
/TT0 1 Tf
0.156 Tw T*
[(T)55.3(ype 1-based drug being used as an oncolytic to)14.9( )]TJ
0.233 Tw T*
[(treat )0.6(advanced )0.6(melanoma.)]TJ
-0.015 Tw 6.82 0 0 6.82 184.3217 598.1717 Tm
(12)Tj
0.233 Tw 11 0 0 11 192.1122 593.9917 Tm
[( )0.5(However)55.2(, )0.5(for )0.5(CFTR,)15.2( )]TJ
0.251 Tw -13.374 -1.182 Td
[(small )0.7(molecule )0.7(therapies )0.6(will )0.6(likely )0.6(dominate )0.7(the)14.9( )]TJ
0.193 Tw T*
[(treatment regime for the near future. Perhaps as)15( )]TJ
0.052 Tw 0 -1.182 TD
[(methods are developed )0.5(that can overcome the low)14.8( )]TJ
0.327 Tw 0 -1.182 TD
[(rates )0.5(of )0.5(infection )0.6(and )0.5(the )0.5(hostile )0.5(immunological)14.8( )]TJ
0.257 Tw T*
[(environment in the diseased lung, )55.5(AA)74.2(V)55.2(-mediated)14.8( )]TJ
0.251 Tw T*
[(therapy )0.5(may )0.6(once )0.6(again )0.6(prove )0.6(useful. )55.8(Advances)15( )]TJ
0.172 Tw T*
[(in nonviral techniques of genetic editing, such as)15( )]TJ
-0.008 Tw T*
(CRISPR/Cas9, may be the key to the future of ther)Tj
0 Tc 0 Tw (-)Tj
0.015 Tc 0 -1.182 TD
(apy for CFTR.)Tj
/TT1 1 Tf
-0.005 Tc 0.005 Tw 10 0 0 10 63 446.9917 Tm
(Keywords:)Tj
/C2_0 1 Tf
10.5 0 0 10.5 113.673 446.9917 Tm
[<00030026005C00560057004C0046000300BF0045005500520056004C0056000F00030026002900370035000F000300440047004800510052001000440056005600520046004C0044005700480047>-5.2<0003>]TJ
/TT0 1 Tf
0 Tw -6.54 -1.19 Td
(virus, gene therapy)Tj
/TT2 1 Tf
0 Tc 10 0 0 10 45 397.4917 Tm
(Financial support:)Tj
/TT0 1 Tf
10.5 0 0 10.5 131.6699 397.4917 Tm
[( )18.2(This publication was supported )]TJ
-8.254 -1.143 Td
[(in part by )17.9(The National Institute of )54.9(Arthritis )]TJ
0 -1.143 TD
(and Musculoskeletal and Skin Diseases of the )Tj
0 -1.143 TD
[(National Institutes of Health under )53.9(A)18.1(ward Number )]TJ
T*
[(R01AR063634. )16.8(The content is solely the responsibility )]TJ
T*
(of the author and does not necessarily represent the )Tj
/C2_0 1 Tf
0 -1.143 TD
<0052004900BF0046004C0044004F00030059004C0048005A005600030052004900030057004B00480003003100440057004C005200510044004F0003002C005100560057004C005700580057004800560003005200490003002B00480044004F0057004B0011>Tj
/TT2 1 Tf
10 0 0 10 45 312.9917 Tm
(From:)Tj
/TT0 1 Tf
10.5 0 0 10.5 73.3301 312.9917 Tm
( Department of Cell Physiology and Molecular )Tj
-2.698 -1.19 Td
[(Biophysics, )17.6(T)111(exas )17.9(T)111(ech University Health Sciences )]TJ
-0.018 Tw 0 -1.19 TD
[(Center)54.7(, )-17.7(Lubbock, TX)]TJ
/TT2 1 Tf
0 Tw 10 0 0 10 45 275.9917 Tm
(Submitted:)Tj
/TT0 1 Tf
10.5 0 0 10.5 97.2168 275.9917 Tm
( 3/28/2018)Tj
/C2_1 1 Tf
10.25 0 0 10.25 45 263.7417 Tm
<00260052005100C0004C0046005700560003005200490003004C0051005700480055004800560057001D>Tj
/TT0 1 Tf
( none)Tj
( )Tj
0 -1.195 TD
(This work is licensed under a Creative Commons )Tj
0 -1.22 TD
(Attribution-ShareAlike 4.0 International License.)Tj
ET
q
0 0 630 810 re
W n
BT
/T1_1 1 Tf
13 0 0 13 327 695.808 Tm
(R)Tj
9.1 0 0 9.1 335.6709 695.808 Tm
(EFE)Tj
/Span<>> BDC
(R)Tj
EMC
(ENCES)Tj
ET
Q
BT
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
10 0 0 10 327 670.808 Tm
( )Tj
EMC
[(1)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.184 Tw 1.8 0 Td
[(Nirenber)17.9(g W)149.9(. )]TJ
/T1_3 1 Tf
0.214 Tw 5.979 0 Td
[(W)54.9(ill Society Be Pr)36.9(epar)36.9(ed?)]TJ
/T1_2 1 Tf
( 1966: Research )Tj
0.117 Tw -5.979 -1.2 Td
[(Cor)-29.8(poration )0.5(for )0.5(Science )55.5(Adv)24.9(ancement. )0.6(Research )0.6(Cor)-29.8(pora)]TJ
0 Tw (-)Tj
-0.055 Tw 0 -1.2 TD
[(tion A)91.8(w)25(ard )-55(Dinner)55(.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(2)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.102 Tw 1.8 0 Td
[(Bordignon )0.5(C, )0.5(Notarangelo )0.5(LD)59.9(, Nobili )0.5(N)25(, et )0.5(al. )0.5(Gene )0.5(ther)]TJ
0 Tw 23.667 0 Td
(-)Tj
0.096 Tw -23.667 -1.2 Td
[(ap)29.8(y in peripheral b)19.8(lood l)24.9(ymphoc)14.9(ytes and bone mar)-29.8(ro)39.8(w for )]TJ
0 Tw T*
[(AD)39.8(A-immunode\037cient patients. )]TJ
/T1_3 1 Tf
(Science)Tj
/T1_2 1 Tf
( 1995;270:470\22675.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(3)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.401 Tw 1.8 0 Td
[(Sibbald B)29.8(. Death b)-4.9(ut one unintended consequence of )]TJ
0 Tw T*
[(gene-therap)29.9(y trial. )]TJ
/T1_3 1 Tf
(CMAJ)Tj
/T1_2 1 Tf
( 2001;164:1612.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(4)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc -0.024 Tw 1.8 0 Td
[(Kim )29.4(W)49.8(O)39.8(. Institutional re)25(vie)24.9(w board \(IRB\) and ethical issues )]TJ
0 Tw T*
(in clinical research. )Tj
/T1_3 1 Tf
-0.06 Tw [(K)39.8(or)36.9(ean )-60(J Anesth)]TJ
/T1_2 1 Tf
0 Tw ( 2012;62:3\22612.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(5)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc -0.002 Tw 1.8 0 Td
[(Zincarelli C, Soltys S, Rengo G, Rabino)39.8(witz JE. )55(Anal)25(ysis of )]TJ
-0.029 Tw T*
[(AA)134.8(V serotypes 1-9 mediated gene e)14.9(xpression )0.5(and tropism in )]TJ
-0.045 Tw T*
(mice after systemic injection. )Tj
/T1_3 1 Tf
-0.105 Tw (Mol Ther)Tj
/T1_2 1 Tf
-0.045 Tw ( 2008;16:1073\2261080.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(6)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.195 Tw 1.8 0 Td
(Schultz BR, Chamberlain JS. Recombinant adeno-associ)Tj
0 Tw (-)Tj
0.085 Tw T*
[(ated vir)-19.7(us transduction )0.5(and inte)14.9(g)-19.8(ration. )]TJ
/T1_3 1 Tf
0.025 Tw (Mol Ther)Tj
/T1_2 1 Tf
0.085 Tw ( 2008;16:)Tj
0 Tw ( )Tj
0 -1.2 Td
(1189\2261199.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(7)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.075 Tw 1.8 0 Td
[(Moss RB)29.7(, Milla C, Colombo J)59.8(, et al. Repeated aerosolized )]TJ
0.148 Tw T*
[(AA)134.8(V)129.9(-CFTR )0.5(for treatment )0.5(of )0.5(c)14.9(ystic )0.5(\037brosis: )0.5(a randomized )]TJ
0.001 Tw T*
(placebo-controlled phase 2B trial. )Tj
/T1_3 1 Tf
-0.059 Tw [(Hum )-60.1(Gene Ther)]TJ
/T1_2 1 Tf
0.001 Tw ( 2007;18:)Tj
0 Tw ( )Tj
T*
(726\226732.)Tj
/T1_0 1 Tf
-0.035 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(8)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
-0.005 Tc 0.139 Tw 1.8 0 Td
[(Flotte )49.7(T)99.9(, Car)-19.7(ter B)29.8(, Conrad C, et al. )54.8(A phase I study of an)-5( )]TJ
-0.089 Tw /Span<>> BDC
T*
( )Tj
EMC
0 0 TD
[(adeno-associated vir)-19.8(us-CFTR gene v)14.9(ector in adult CF patients)-5( )]TJ
0 Tw 0 -1.2 TD
(with mild lung disease. )Tj
/T1_3 1 Tf
-0.06 Tw [(Hum )-60(Gene Ther)]TJ
/T1_2 1 Tf
0 Tw ( 1996;7:1145\2261159.)Tj
/T1_0 1 Tf
-0.035 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(9)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
-0.005 Tc -0.094 Tw 1.8 0 Td
[(Loring HS, ElMallah MK, Flotte )49.3(TR. De)24.9(v)14.9(elopment of rAA)134.8(V2-)]TJ
0.03 Tw T*
[(CFTR: Histor)-19.8(y of the F)19.8(irst rAA)134.8(V )49.8(V)110.9(ector Product to be Used)-5( )]TJ
0 Tw T*
(in Humans. )Tj
/T1_3 1 Tf
[(Hum Gene )59.8(Ther Methods )]TJ
/T1_2 1 Tf
0.005 Tw [(2016;27:49\226)-5(58.)]TJ
/T1_0 1 Tf
-0.02 Tc 0.02 Tw -1.8 -1.2 Td
(10.)Tj
/Span<>> BDC
1.16 0 Td
( )Tj
EMC
/T1_2 1 Tf
-0.033 Tw 0.64 0 Td
[(Flotte )50.2(TR, Schwieber)-19.7(t EM, Zeitlin )0.5(PL, Car)-19.7(ter BJ)59.9(, )0.5(Guggino )30.2(WB)29.8(.)-20( )]TJ
-0.094 Tw T*
[(Cor)-29.8(relation betw)34.9(een DN)35(A transfer and c)14.9(ystic \037brosis airw)24.9(a)34.9(y epi)]TJ
0 Tc 0 Tw (-)Tj
-0.02 Tc 0.009 Tw T*
[(thelial )0.5(cell )0.6(cor)-29.8(rection )0.6(after )0.5(recombinant )0.6(adeno-)]TJ
/Span<>> BDC
( )Tj
EMC
17.912 0 Td
[(associated )0.6(vir)-19.8(us)-20( )]TJ
0 Tw -17.912 -1.2 Td
[(serotype 2 gene therap)29.8(y)85(. )]TJ
/T1_3 1 Tf
-0.06 Tw [(Hum )-60(Gene Ther)]TJ
/T1_2 1 Tf
0 Tw ( 2005;16:921\226928.)Tj
/T1_0 1 Tf
0 Tc -1.8 -1.2 Td
(11.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.121 Tw 0.58 0 Td
[(Moss RB)29.8(, Rodman D)59.9(, Spencer L)91.8(T)99.9(, et al. Repeated adeno-)]TJ
/Span<>> BDC
( )Tj
EMC
0.176 Tw T*
[(associated vir)-19.8(us serotype 2 aerosol-mediated c)14.9(ystic \037bro)]TJ
0 Tw (-)Tj
0.155 Tw T*
[(sis transmembrane re)14.9(gulator gene transfer to the lungs of )]TJ
0.267 Tw T*
[(patients )0.5(with )0.5(c)14.9(ystic \037brosis: )0.5(a )0.5(multicenter)39.9(, doub)19.8(le-b)19.8(lind)59.8(, )]TJ
-0.25 Tw /Span<>> BDC
T*
( )Tj
EMC
[(placebo-controlled )-249.9(trial. )]TJ
/T1_3 1 Tf
0 Tw 9.859 0 Td
(Chest)Tj
/T1_2 1 Tf
( 2004;125:509\226521.)Tj
/T1_0 1 Tf
-11.659 -1.2 Td
(12.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.018 Tw 0.58 0 Td
[(FD)39.8(A. )54.8(Appro)44.9(v)14.9(ed Cellular and Gene )49.7(Therap)29.8(y Products. 2018. )]TJ
0.047 Tc -0.047 Tw T*
[(h)0.5(tt)0.5(p)0.5(s:)0.5(//)0.5(w)0.5(w)0.5(w)90.3(.f)0.5(d)0.5(a)0.5(.g)0.5(o)45.4(v/)0.5(B)0.5(io)0.5(lo)25.4(g)0.5(ic)0.5(s)0.5(B)0.5(lo)0.5(od)0.5(V)111.3(a)0.5(c)0.5(c)0.5(in)0.5(e)0.5(s/)0.5(C)0.5(el)0.5(l)0.5(ul)0.5(ar)]TJ
0 Tc 0 Tw 24 0 Td
( )Tj
-24 -1.2 Td
[(GeneTherap)29.9(yProducts/Appro)45(v)14.9(edProducts/def)-9.8(ault.htm.)]TJ
ET
endstream
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 54.1778 Tm
(The Southwest Respiratory and Critical Care Chronicles 2018;6\(23\):1\226\
3)Tj
ET
endstream
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 45 68.8957 cm
0 0 m
540 0 l
S
Q
10 M
q 1 0 0 1 45 740.2762 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 751.5262 Tm
[(Current Progress of )36.7(Adeno-Associated-V)16.8(irus-Based Therapy for the T)73.7(reatment of Cystic Fibrosis in Humans)]TJ
/Span<>> BDC
( )Tj
EMC
64.609 0 Td
(Sutton)Tj
ET
endstream
endobj
31 0 obj
<>
endobj
32 0 obj
<>
endobj
33 0 obj
<>stream
H\j0\/Jڴ[bR["o?)*̐3/cQ's%n8tP_Nox_VJH\NÈmNeN>hs㤟}wJޢ~:èW:ϵǚTkբNfٲߌӒ4S:k1:C_9UV4ri
EvwUrjEQH]Lq*2o7 ;s7o[fւRXւ6̒